Perioperative Bleeding Management in Pediatric Patients: rVWF
- Recombinant von Willebrand factor (rVWF) represents a potential paradigm shift in managing children with bleeding disorders undergoing surgery, according to Dr.
- von Willebrand factor (VWF) is a crucial protein in the blood involved in blood clotting.
- Traditional treatments often involve administering desmopressin (DDAVP) or plasma-derived VWF concentrates. DDAVP stimulates the release of VWF from storage sites in the body, but its effectiveness varies, and...
“`html
Recombinant von Willebrand Factor Shows Promise in Pediatric Surgical Bleeding Management
Recombinant von Willebrand factor (rVWF) represents a potential paradigm shift in managing children with bleeding disorders undergoing surgery, according to Dr. Shayla Bergmann, a clinical professor of pediatric hematology at the Medical University of South Carolina. Findings from a significant multicenter study, initially presented at the American Society of Hematology (ASH) 2025, suggest rVWF could offer a more predictable and effective approach to controlling bleeding during and after surgical procedures.
Understanding von Willebrand Factor and Bleeding Disorders
von Willebrand factor (VWF) is a crucial protein in the blood involved in blood clotting. It helps platelets adhere to injury sites and carries factor VIII, another essential clotting factor. deficiencies in VWF lead to von Willebrand disease (VWD), the most common inherited bleeding disorder, affecting approximately 1% of the population according to the World Federation of Hemophilia. Children with VWD, or other bleeding disorders, face significant risks during surgery, requiring careful management to prevent excessive bleeding.
Traditional treatments often involve administering desmopressin (DDAVP) or plasma-derived VWF concentrates. DDAVP stimulates the release of VWF from storage sites in the body, but its effectiveness varies, and it can cause fluid retention. Plasma-derived concentrates carry a risk of viral transmission, although modern manufacturing processes have significantly reduced this risk.
The Study: rVWF in Pediatric Surgery
Dr. Bergmann’s study investigated the efficacy and safety of rVWF in a cohort of children undergoing various surgical procedures. While detailed study data is pending full publication, initial reports indicate that rVWF demonstrated effective hemostasis (control of bleeding) in the majority of patients. the study tracked bleeding events, VWF levels, and adverse effects.
the study’s design involved administering rVWF before, during, and after surgery, with dosages tailored to each patient’s weight and the type of procedure. Researchers monitored patients for complications such as thrombosis (blood clots) and antibody growth against rVWF. Preliminary findings suggest a lower incidence of thrombosis compared to some plasma-derived products.
Key Data Points (Preliminary)
| Metric | Value (Based on ASH 2025 Presentation) |
|---|---|
| Number of patients | Not yet publicly disclosed. |
| Procedures Performed |
|